Loading stock data…
Stryker Corporation (SYK)
$303.13-4.86 (-1.58%)
Pre-Market$301.69-1.44 (-0.48%)· Last close Sep 4
Stryker Corporation operates as a medical technology company in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Stryker Corporation in the Healthcare sector is trading at $303.13 with a market capitalization of $116.3B. Wall Street consensus targets $382.72 (25 analysts), implying a +26.3% move over the next 12 months. The stock is currently near its 52-week low of $281.00, remaining 10.1% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +26.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 30) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.59B↑ | $6.02B↓ | $7.17B↑ | $6.06B↑ | $6.02B |
| Gross Profit | $4.50B↑ | $3.81B↓ | $4.63B↑ | $3.85B↑ | $3.84B |
| Operating Income | $1.66B↑ | $936.00M↓ | $1.81B↑ | $1.21B↑ | $1.17B |
| Net Income | $1.28B↑ | $745.00M↓ | $849.00M↓ | $859.00M↓ | $884.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$116.27B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
31.45
Beta
Defensive asset. Lower volatility than the S&P 500.
0.77
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.15%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.55%
Volume
Today's trading volume
2.35M
Recent News
Stryker (SYK) is Buying ZuriMED. Can FiberLocker Strengthen its Shoulder Portfolio?
Stryker Corporation (NYSE:SYK) signed a definitive agreement to acquire privately held ZuriMED, which would add the commercialized FiberLocker System to its shoulder portfolio upon closing. FiberLocker is designed to reinforce rotator-cuff repairs by strengthening the connection between a surgical patch and tendon tissue. The transaction remains subject to customary closing conditions, while the purchase price […]
How Much Upside Can BSX Stock's Growth Deliver?
While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.
Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money
Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.
Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?
BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.
Stryker Launches FDA-Cleared Apple Vision Pro Surgical App
SYK's FDA-cleared SportSuite Vision brings Apple Vision Pro into hip arthroscopy, strengthening its digital surgery push and Sports Medicine portfolio.